Login
Boston Scientific NYSE: BSX
Boston Scientific Corp. develops, manufactures, and markets medical devices in the Cardiovascular, Rhythm Management, and MedSurg segments
| Name | Boston Scientific |
| Ticker | BSX |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Medical Devices |
|
Price
52W Low/High |
40.86
33.15 / 42.23 |
| Momentum | Neutral |
| Market cap | 58 B |
| 1Y Total Return |
15.26%
Weak |
| 1Y Volatility |
32.98%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Boston Scientific Corp. develops, manufactures, and markets medical devices in the Cardiovascular, Rhythm Management, and MedSurg segments
Details
| Ticker | BSX |
| Name | Boston Scientific |
| ISIN | US1011371077 |
| CUSIP | 101137107 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/15/21
| Close Price | 40.86 |
| 52W Low/High | 33.15 / 42.23 |
| Market cap | 58 B |
| 1Y Total Return |
15.26%
Weak |
| 1Y Volatility |
32.98%
Less Risk |
| Beta | 1.10 |
| PE (trailing) |
15.66
Low |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 36.5% |
| Cash from Op. / Cur. Liabilities | 0.46 |
| Diluted Earnings / Share | 2.61 |
| ROE | 29.2% |
| ROIC | 1.1% |
| Price / Revenue | 5.8 |
| Price / Book | 3.8 |
| Price / CF | 38.8 |
| Current Ratio | 1.9 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.60 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
10,109
|
10,392
|
9,670
|
8,830
|
8,173
|
7,386
|
|
| Gross Profit |
6,792
|
7,398
|
6,913
|
6,292
|
5,794
|
5,228
|
|
| R&D |
1,165
|
1,154
|
1,088
|
989
|
908
|
841
|
|
| EBITDA |
1,064
|
2,240
|
2,429
|
1,839
|
754
|
137
|
|
| Operating Income |
80
|
1,627
|
1,506
|
1,106
|
80
|
-548
|
|
| Net Income exc. Extra |
3,704
|
1,090
|
670
|
843
|
81
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
1,431
|
1,412
|
1,404
|
1,394
|
1,380
|
1,344
|
|
| EPS exc. Extra |
2.61
|
0.77
|
0.48
|
0.61
|
0.06
|
-0.29
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
30,845
|
26,756
|
20,379
|
18,636
|
17,697
|
18,215
|
|
| Cash, Eq & Invt ShortTerm |
2,022
|
277
|
168
|
210
|
237
|
350
|
|
| Total Current Assets |
6,160
|
4,847
|
3,971
|
3,478
|
3,181
|
3,462
|
|
| Total Non-Current Assets |
24,685
|
21,909
|
16,408
|
15,158
|
14,516
|
14,753
|
|
| Intangibles |
16,934
|
18,089
|
13,885
|
12,665
|
12,336
|
12,696
|
|
| Total Liabilities |
15,281
|
17,057
|
12,090
|
11,048
|
11,215
|
11,805
|
|
| Total Current Liabilities |
3,302
|
4,254
|
5,082
|
4,828
|
3,016
|
2,238
|
|
| Long Term Debt |
11,979
|
12,803
|
7,008
|
6,220
|
8,199
|
9,567
|
|
| Shareholder equity |
15,564
|
9,699
|
8,289
|
7,588
|
6,482
|
6,410
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
1,527
|
1,163
|
975
|
1,418
|
926
|
711
|
|
| Depreciation |
1,011
|
894
|
844
|
815
|
769
|
725
|
|
| Cash from Investing |
-313
|
-5,587
|
-1,615
|
-1,253
|
-525
|
-2,099
|
|
| Capex |
277
|
362
|
289
|
407
|
265
|
241
|
|
| Cash from Financing |
388
|
4,122
|
939
|
206
|
-471
|
1,499
|
|
| Stock Issued |
1,032
|
54
|
45
|
13
|
64
|
40
|
|
| Debt (LT) Issued |
-1,729
|
4,206
|
913
|
253
|
-445
|
1,580
|
|
| Free Cash Flow |
-1,398
|
394
|
908
|
2,906
|
1,363
|
-2,591
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
36.5%
|
10.5%
|
6.9%
|
9.5%
|
1.0%
|
-
|
|
| NCFO / Op.Income |
1,908.8%
|
71.5%
|
64.7%
|
128.2%
|
1,157.5%
|
-
|
|
| Current Ratio |
1.9
|
1.1
|
0.8
|
0.7
|
1.1
|
1.5
|
|
| Financial Leverage D/E |
0.60
|
1.12
|
0.80
|
0.75
|
0.84
|
0.91
|
|
| Return on Capital Avg |
1.1%
|
7.7%
|
1.6%
|
5.9%
|
-0.1%
|
-21.5%
|
|
| Return on Shareholder Equity |
29.2%
|
12.1%
|
8.4%
|
12.0%
|
1.3%
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available